Daraxonrasib (also called RMC-6236) is a direct “RAS(ON)” multi-selective inhibitor designed to target active, GTP-bound RAS, including a broad set of KRAS variants (not just KRAS G12C). The most recent public updates I can see focus on its clinical development in RAS-mutant pancreatic ductal adenocarcinoma (PDAC).[6][7][8][9]
If you tell me whether you mean (a) KRAS mutations specifically in pancreatic cancer or (b) another indication (e.g., lung/colorectal/endometrial or something else), I can tailor the “latest news” roundup to that exact context.
Notably, a greater than 50% decrease in RASSearch term VAF from baseline was observed in 93% of patients with KRAS G12XSearch term mutations (n = 56/60) and 90% of those with RAS mutations (n = 66/73).
trial.medpath.comThe targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.
www.news-medical.netIn conclusion, daraxonrasib has superiority over selective KRAS mutant inhibitors specifically targeting KRAS^G12C^, KRAS^G12D^, or KRAS^G12V^. First, daraxonrasib has a broad-spectrum activity against both mutant and WT KRAS, HRAS, and NRAS isoforms.
pmc.ncbi.nlm.nih.govKRAS mutations, which induce proliferative signaling driving many human cancers, are detectable in a small subset of osteosarcoma patients. The recently developed pan-KRAS inhibitor daraxonrasib, also known as RMC-6236, is capable of targeting a ...
pmc.ncbi.nlm.nih.govA new drug targeting the KRAS mutation is transforming outcomes for pancreatic cancer patients, potentially opening doors for other cancers.
longevitytoday.comTreatment with daraxonrasib at the phase 3 dose of 300 mg was well tolerated, had favorable dose intensity, and showed efficacy in RAS–mutated PDAC.
www.onclive.comThe targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.
www.mdanderson.orgDaraxonrasib earned FDA breakthrough therapy designation for previously treated metastatic PDAC harboring KRAS G12X mutations.
www.onclive.comThe targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard treatments for patients with RAS-mutant pancreatic cancer, according to results of a Phase 1/2 trial led by researchers at The University of Texas MD Anderson Cancer Center.
www.eurekalert.org